M-1095

Summary

M-1095 (CHEMBL4298023) is a phase-3 clinical-stage unknown; indicated across 3 conditions including hidradenitis suppurativa and psoriasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298023
Name	M-1095
Type	Unknown
Max phase	3

Also known as: ALX-0761, ALX0761, M-1095, M1095, Sonelokimab

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hidradenitis suppurativa	3	MONDO:0006559	EFO:1000710
psoriasis	2	MONDO:0005083	EFO:0000676
psoriatic arthritis	2	MONDO:0011849	EFO:0003778

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06411379	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06411899	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06641076	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
NCT06641089	PHASE3	RECRUITING	Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06768671	PHASE3	ACTIVE_NOT_RECRUITING	An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT07007637	PHASE3	ENROLLING_BY_INVITATION	A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07223138	PHASE3	ENROLLING_BY_INVITATION	A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
NCT03384745	PHASE2	COMPLETED	A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
NCT05322473	PHASE2	COMPLETED	Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
NCT05640245	PHASE2	COMPLETED	Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis
NCT06994936	PHASE1	COMPLETED	An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).